Index

^{18}FET-PET, 163
^{18}F-Fluorodeoxyglucose PET, 180
^{18}F-Fluoromethylcholine, 185
^{18}F-Fluorothymidine, 186
1p/19q, 32
3D reconstruction, 386
5-ALA, 199, 200, 246–248, 289, 290

A

Acoustic energy, 416
Actin rearrangement, 79
Adhesion complexes, 79
Age, 145
Age at recurrence, 287
Amino-acid PET, 182
Anatomic prevalence, 29
Angiogenesis, 5–9, 95–97, 99, 101–104, 114, 306, 318, 319, 323–325
Angiogenesis inhibitors, 20, 306
Animal trials, 387
Apoptosis, 118
Arborizing catheter, 359
ATRX, 32
Autophagy, 61
Auxonal guidance molecules, 80
Axial T2-weighted MRI, 265

B

Bevacizumab, 203, 207–209, 216
Biomarkers, 16, 18, 100
Biopsy, 160
Bipolar probe, 376
Blood-brain barrier, 343, 395
Blood-brain barrier disruption, 380
Blue excitation light, 248
Brachytherapy, 206

C

Cadherins, 83
Catherters, 362
Cell proliferation, 112, 118
Cell sorting, 65
Cell-line xenografts, 132
Cellular protrusions, 79
Cerebral gliomas, 263
Chemotherapy, 223, 292, 305
Chondroitin sulfate proteoglycans, 78
Classification, 9, 146
Clinical features, 302
Clinical outcome, 283
Clinical practice, 155
Clinical trials, 16, 203, 208, 209, 211–214, 217–221
Clinically relevant model, 405
Combination regimens, 207, 210, 216
Combination treatment, 206
Complemetary treatment, 200
Complications, 290
Confusion, 226
Contrast-enhanced MRI, 181
Controllable drug delivery, 397
Convection-enhanced delivery, 359, 411
Copy number aberrations, 13
Cortical mapping, 263
Current standards, 197
Cytoreduction, 291

Cytoskeleton, 78
Cytotoxic therapy, 341

D

Depression, 226
Deregulated lncRNAs, 109
Deregulated miRNAs, 101
Differential diagnosis, 157
Differentiation, 178
Diffuse glioma, 74
Direct cortical stimulation, 276
DNA methylation, 44, 63
Dose-fractionation schedule, 201
Drug resistance, 115

E

EA5-Fc-PE38QQR, 349
ECM, 322
Effect of treatment, 35
EGFR/PTEN/AKT/mTOR pathway, 34
Electric stimulation mapping, 275
Eloquent cortex, 270
EMT, 82
EOL care, 226
Eph receptors, 349
EphA2, 344, 345
EphA3 receptor, 346
Ephrins, 81
Epidemiology, 29, 143, 298
Epigenetic mechanisms, 43
Epigenetic regulation, 62
Epigenome, 10
Epithelial to mesenchymal transition, 8
Ethnicity, 146
Extent of resection, 246, 289
External beam radiation, 201
Extracellular matrix, 76

F

FET-PET, 163
Fluorescence-guided surgery, 246
Fluorophores, 247
Follow-up, 162
Fractionated radiation, 206
Functional MRI, 266
Functional tests, 64
Future perspectives, 165

G

Galectins, 78
GBM vasculature, 318
G-CIMP, 33
Gender, 145
Gene ontology, 46
Genetic alterations, 5
Genetically engineered mouse models, 134
Genetics, 34
Genome, 10
Genomic abnormalities, 9
Genomic landscape, 12
Genomics, 3
Gliadel wafer, 19
Glial cell compartment, 320
Glioblastoma, 3, 27, 43, 59, 73, 95, 131, 143, 155, 175, 243
Glioblastoma in the elderly, 222
Glioblastoma models, 327
Glioblastoma therapy, 197
Glioma cell migration, 80
Glioma cell motility, 73
Glioma extent, 159
Glioma initiation, 32
Glioma progression, 34
Glioma stem cells, 319

Glioma subtypes, 12
Glioma transformation, 35
Gliomagenesis, 31
Glutamate signaling, 80
Glycoproteins, 78
Go or grow, 75
Growth factor receptor inhibitors, 19
GSC differentiation, 119
GSCS, 108

H

Heterogeneic nature, 316
High-frequency irreversible electroporation, 373, 415
High-intensity focused ultrasound, 396
Histone modifications, 62
Hydrodynamic model, 80
Hypermethylated genes, 46
Hypermethylation, 47
Hypomethylation, 48, 53
Hypoxia, 75
Hypoxia-PET, 186

I

IDH, 32
IL-13RA2, 344
IL-13RA2, 345
Image-guided, 395
Immune cells, 321, 331
Immune evasion, 115
Implantable wafers, 201
Improving resection, 290
Incidence, 144
IncRNAs, 118
Indocyanine green, 247
Infiltration, 74
Infusion distribution, 367
Inherent section bias, 283
Intartentorial approaches, 253
Integrins, 77
Interstitial fluids, 323
Intracranial pressure, 226
Intraoperative technologies, 246
Intraoperative videoangiography, 249
Intratumor heterogeneity, 6
Intravenous anesthetics, 245
Invasion, 114, 119
Ion channels, 80
Irreversible electroporation, 373, 413

K

Karnofsky performance scale, 284

L

LNCRNA, 53
Long Coding RNAs, 117

M

MacDonald criteria, 175, 177, 178, 207
Magnetic resonance imaging, 264
Magnetoencephalography, 267
Maintenance therapy, 201
MassARRAY, 49
Material properties, 385
Matrix metalloproteinases, 77
Maximizing local access, 341, 357, 373, 395, 405
MeDIP-Chip, 46
Methylomes, 44
Microenvironment, 315
MicroRNAs, 97

Microscopic features, 299
Migration, 114, 119
Minimal residual disease, 292
miR-101, 53
miRNA, 51, 53
MiRNA biogenesis, 98
MiRNA deregulation, 97
miRNA therapeutics, 116
Miscellaneous agents, 20
Molecular biology, 299, 300
Molecular classification, 30
Molecular genetics, 27
Molecular landscape, 30
Molecular mechanisms, 73
Monopolar probe, 376
Monotherapy, 207, 210, 216
Mouse models, 131
Multimodality, 165
Muscle relaxants, 246
Mutated genes, 13

N

Netrins, 81
Neuroimaging, 302
Neuronavigation, 250
Neuropsychological assessment, 268
New therapeutic approaches, 405
Newer drugs, 307
Nitrosourea, 207–209
Noncoding RNA, 95
Novel PET tracers, 187
Novel Radiotracers, 165

O

Opening of the BBB, 396
Optimization of catheters, 361
Outcome, 143, 149, 307

P

P161NK4A/RB1 pathway, 35
Park bench position, 255
Pathogenesis, 4
Pathological variants, 300
Pathology, 299
Patient position, 250
Patient-derived xenografts, 133
Pediatric glioblastoma, 297
Perioperative evaluation, 245
PET, 175
PET imaging, 155
Pore formation, 376
Positron emission tomography, 268
Postoperative care, 257
Preclinical, 387, 411
Preoperative planning, 264
Primary diagnosis, 157
Primary GBM, 10
Prognostic factors, 148, 149
Prognostication, 165
Progression, 162
Prone position, 253
Pseudoprogression, 162

Q

QUAD-CTX, 350, 351

R

Radiation, 37, 161
Radiation therapy, 305
Radiological diagnosis, 282
Radionecrosis, 162
Radiotherapy, 223
RANO criteria, 175, 178, 185, 283
Recurrence, 178
Recurrent glioblastoma, 204

Recurring glioblastoma, 281
Re-irradiation, 205
Remote-controlled, 395
Reoperation, 281
Resection, 160, 263
Resistance, 119
Reversible electroporation, 375
Risk factors, 148

S

Scales to predict survival, 289
Secondary GBM, 10
Secondary glioblastoma, 27
Second-line chemotherapy, 207
Secreted mRNAs, 100
Sedimentation field-flow fractionation, 65
Seizures, 225
Semaphorins, 81
Seven ports, 365
Shadowgraphy, 364
Single port, 365
Single-port microneedle catheter, 363
Site, 145
Sitting position, 254
SLIT/ROBO, 81
SLUG, 83
Small GTPases, 78
SNAIL, 83
Soluble factors, 323
Somatic mutation, 12
Somatosenory evoked potentials, 275
Spontaneous canine gliomas, 407
Standards of care, 197
Stem cell identification, 61
Stem cells, 397
Stem-like cells, 59
Stemness, 112
Stereostatic glioblastoma ablation, 414
Stereostatic radiosurgery, 205
Stupp protocol, 60, 243
Subclassification, 291
Supine position, 251
Supportive care, 225
Supportive environment, 317
Supratentorial approaches, 251
Surface anatomical landmarks, 269
Surgery, 198, 223, 304
Surgical considerations, 268
Surgical management, 243
Surgical navigation, 274
Surgical risks, 290
Surgical series, 284
Surgical technique, 273
Survival, 148
Syngenic mouse models, 135
Systemic brain tumor therapy, 395, 396

T

Targeted therapeutic agents, 17
Targeted therapy, 202, 306
Temozolamide, 18, 19, 36, 200, 201, 203, 210, 211
Temperature profile, 385
TERT, 33
TGF-β, 82
Therapeutic deliveries, 341, 359, 373, 395, 405
Therapeutic prediction, 16
Therapeutic response, 119
Therapeutic targeting, 330
Therapy, 395
Therapy response assessment, 175, 177
Tissue diagnosis, 291
Tissue mechanics, 322

Tissue phantoms, 359
TP53, 32
TP53/MDM2/P14ARF pathway, 35
Transcortical mangnetic stimulation, 267
Transcriptome, 10
Treatment, 176
Treatment planning, 160, 382
Treatment response, 162
Treatment routes, 325
Treatment-related effects, 178
Tumor cell, 315
Tumor microenvironment, 318, 328, 329
Tumor-treating electric fields, 221
TWIST, 83

V

Vascular endothelial growth factor, 301
Vasculature, 330
Viability, 112

W

Whilte light, 248

X

Xenografts, 132

Z

ZEB, 83